Safety and Efficacy of CBX129801 in Patients With Type 1 Diabetes

Completed · Phase 2

Conditions studied: Diabetic Peripheral Neuropathy

In brief

The purpose of the study is to determine the beneficial effects of CBX129801 (PEGylated synthetic human C-peptide) following weekly subcutaneous administration for 12 months in type 1 diabetes mellitus patients (T1DM) with mild to moderate diabetic peripheral neuropathy (DPN).

Key facts

Study ID

NCT01681290

Run by

Cebix Incorporated

People needed

250

Starts

2012-10-01

Expected to finish

2015-01-01

Last updated by the study team

2015-01-30

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Study site — Escondido, California, United States
• Study site — Fresno, California, United States
• Study site — Irvine, California, United States
• Study site — Los Angeles, California, United States
• Study site — San Diego, California, United States
• Study site — San Francisco, California, United States
• Study site — Torrance, California, United States
• Study site — Tustin, California, United States
• Study site — Walnut Creek, California, United States
• Study site — Atlanta, Georgia, United States
• Study site — Decatur, Georgia, United States
• Study site — Idaho Falls, Idaho, United States
• Study site — Boston, Massachusetts, United States
• Study site — Ann Arbor, Michigan, United States
• Study site — Butte, Montana, United States
• Study site — Omaha, Nebraska, United States
• Study site — Las Vegas, Nevada, United States
• Study site — New York, New York, United States
• Study site — Dallas, Texas, United States
• Study site — Houston, Texas, United States
• Study site — Houston, Texas, United States
• Study site — San Antonio, Texas, United States
• Study site — Toronto, Ontario, Canada
• Study site — Laval, Quebec, Canada
• Study site — Gothenburg, Sweden

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.